Hydroxycut Product Recall

HYDROXYCUT PRODUCT RECALL

May 1, 2009 - the Food and Drug Administration (FDA) advised people to immediately stop using the dietary supplement (weight loss supplement), Hydroxycut, linking it to serious liver injuries and death. Hydroxycut products are dietary supplements that are marketed for weight-loss, as fat burners, as energy-enhancers, as low carb diet aids, and for water loss. Hydroxycut is available in most grocery stores, health food stores and local pharmacies.

In its warning, the FDA identified 23 reports of Hydroxycut causing liver damage.

The maker of Hydroxycut has agreed to the recall of all fourteen (14) of its products. The recalled products are:

Hydroxycut Regular Rapid Release Caplets
Hydroxycut Caffeine-Free Rapid Release Caplets
Hydroxycut Hardcore Liquid Caplets
Hydroxycut Max Liquid Caplets
Hydroxycut Regular Drink Packets
Hydroxycut Caffeine-Free Drink Packets
Hydroxycut Hardcore Drink Packets (Ignition Stix)
Hydroxycut Max Drink Packets
Hydroxycut Liquid Shots
Hydroxycut Hardcore RTDs (Ready-to-Drink)
Hydroxycut Max Aqua Shed
Hydroxycut 24
Hydroxycut Carb Control
Hydroxycut Natural

Hydroxycut products are manufactured by Iovate Health Sciences, Inc. of Ontario, Canada and distributed in the U.S. by Iovate Health Sciences USA Inc., near Buffalo, New York.

SHELLER, P.C. is investigating Hydroxycut claims. We are reviewing cases in which a person taking Hydroxycut has suffered liver failure, a liver transplant or death from liver failure.

Please email me at chomolash@sheller.com or call me at (215) 790-7379 with any questions regarding your potential case.

Tysabri Linked to Liver Injury, Including Death

Drugmakers Biogen Idec Inc. and Elan Corp. Plc. have warned doctors of significant liver injury, including markedly elevated serum hepatic enzymes and elevated total bilirubin, after taking the multiple sclerosis drug Tysabri. These adverse effects occurred as early as six days after the first dose of the drug. The combination of transaminase elevations and elevated bilirubin without evidence of obstruction is recognized as an important predictor of severe liver injury that may lead to death or the need for a liver transplant in some patients. Tysabri should be discontinued in people with jaundice or other evidence of significant liver injury.

The companies co-market the drug, with Biogen taking the lead in the U.S. The drug Tysabri is also used to treat people with Crohn's disease.

Claudine Homolash is a personal injury attorney in Philadelphia, PA, who focuses her practice representing individuals who have been injured by dangerous drugs and medical devices. Ms. Homolash was recently nominated for the National Multiple Sclerosis Society's 2008 MS Leadership Class and is familiar with the physical harm Tysabri may cause to certain individuals.